Year To Quarter End Consolidated Statement Of Comprehensive Income

TAIKO PHARMACEUTICAL CO., LTD. - Filing #7339470

Concept 2024-01-01 to
2024-03-31
2023-01-01 to
2023-03-31
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
472,000,000 JPY
-243,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
94,000,000 JPY
JPY
Foreign currency translation adjustment
57,000,000 JPY
8,000,000 JPY
Other comprehensive income
152,000,000 JPY
8,000,000 JPY
Comprehensive income
624,000,000 JPY
-234,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
624,000,000 JPY
-234,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.